Honey bee as apitoxin, carries several active components, the most abundant of which is melittin, and the most biologically active are enzymes, particularly phospholipase A2. Bee venom is under laboratory and clinical research for its potential properties and uses in reducing risks for adverse events from bee venom therapy, rheumatoid arthritis, and use as an immunotherapy for protection against allergies from insect stings. Bee venom products are marketed in many countries, but, as of 2018, there are no approved clinical uses for these products which carry various warnings for potential allergic reactions. With an increased number of honey bees in a specific
Toxicology of red imported fire ant venom entire body of the ant and not just the venom, and unlike fire ant venom immunotherapy (which is occasionally used), WBE contains venom proteins. To reduce a patient's sensitivity to the venom, gradual increases of dose extracts are injected into the body. WBE immunotherapy appears to be very effective in preventing systemic reactions; in one study of participants who completed WBE immunotherapy, two out of fifteen participants suffered from allergic reactions upon being stung 18 months after immunotherapy. As mentioned, fire ant venom immunotherapy is occasionally used, and studies show it can reduce the risk of systemic reactions. In fact,